Incyte Corporation (INCY)
NASDAQ: INCY · Real-Time Price · USD
59.17
+0.20 (0.34%)
At close: Apr 25, 2025, 4:00 PM
59.25
+0.08 (0.14%)
After-hours: Apr 25, 2025, 5:13 PM EDT
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
$1,620,641
Profits / Employee
$12,463
Market Cap
11.45B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2,617 | 93 | 3.68% |
Dec 31, 2023 | 2,524 | 200 | 8.61% |
Dec 31, 2022 | 2,324 | 230 | 10.98% |
Dec 31, 2021 | 2,094 | 321 | 18.10% |
Dec 31, 2020 | 1,773 | 317 | 21.77% |
Dec 31, 2019 | 1,456 | 89 | 6.51% |
Dec 31, 2018 | 1,367 | 159 | 13.16% |
Dec 31, 2017 | 1,208 | 228 | 23.27% |
Dec 31, 2016 | 980 | 288 | 41.62% |
Dec 31, 2015 | 692 | 104 | 17.69% |
Dec 31, 2014 | 588 | 107 | 22.25% |
Dec 31, 2013 | 481 | 68 | 16.46% |
Dec 31, 2012 | 413 | 45 | 12.23% |
Dec 31, 2011 | 368 | 121 | 48.99% |
Dec 31, 2010 | 247 | 26 | 11.76% |
Dec 31, 2009 | 221 | 9 | 4.25% |
Dec 31, 2008 | 212 | 16 | 8.16% |
Dec 31, 2007 | 196 | 10 | 5.38% |
Dec 31, 2006 | 186 | 9 | 5.08% |
Dec 31, 2005 | 177 | -9 | -4.84% |
Dec 31, 2004 | 186 | -268 | -59.03% |
Dec 31, 2003 | 454 | -37 | -7.54% |
Dec 31, 2002 | 491 | -94 | -16.07% |
Dec 31, 2001 | 585 | -737 | -55.75% |
Dec 31, 2000 | 1,322 | 214 | 19.31% |
Dec 31, 1999 | 1,108 | 241 | 27.80% |
Dec 31, 1998 | 867 | 191 | 28.25% |
Dec 31, 1997 | 676 | 218 | 47.60% |
Dec 31, 1996 | 458 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
INCY News
- 2 days ago - Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 - Business Wire
- 4 days ago - Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Business Wire
- 17 days ago - Incyte to Report First Quarter Financial Results - Business Wire
- 20 days ago - Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 27 days ago - These 20 worst-performing stocks in the S&P 500 sank 17% or more in March - Market Watch
- 4 weeks ago - Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico - GlobeNewsWire
- 5 weeks ago - Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib - Seeking Alpha
- 5 weeks ago - Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results - Investopedia